Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
The Sugar Trehalose
Free NEWS Letter
Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login

Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials

Main Menu
Home
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
NEWS
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Disclaimer
Sitemap
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One


Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)

Who's Online
We have 18 guests online
Report: Merck Announcing Major Restructure
Pharmaceutical Industry Making Major Changes Merck & Co. Inc. may cut thousands of jobs and enact other changes as part of a major restructuring plan the pharmaceutical maker was expected to announce this week, according to a published report.

The Wall Street Journal, citing a person familiar with the matter, reported Saturday that the plan _ expected to be announced on Monday _ includes cuts in operations within and outside the United States and a tighter focus on certain disease-research areas. Last month, Merck cut 825 jobs worldwide.

"As Merck has stated, we are carefully considering a variety of options to help improve our core business fundamentals and ultimately position Merck to meet the challenges the company faces now and in the future," Merck spokesman Christopher Loder said Sunday. "We have committed to provide details about our plans as well as milestones and metrics that can be used to evaluate our progress against them by the end of the year, and we will."

Any such reorganization would come near the start of the first federal trial over Merck's withdrawn painkiller Vioxx, which is due to start Tuesday in Houston.

Whitehouse Station-based Merck, the world's No. 5 drugmaker, pulled Vioxx from the market in September 2004 when its own study showed the painkiller could double risk of heart attack or stroke if taken for 18 months or longer.

Besides several thousand liability lawsuits stemming from the Vioxx recall, Merck faces the loss of patent protection in 2006 for its top- selling cholesterol drug, Zocor. The company's share price is trading at about half its value before Vioxx was removed from the market.

Merck plans its annual business briefing for investors on Dec. 15.

NEW YORK

Copyright 2005 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Source